Clinical Trials Sponsored by Medi Pharma Vision

Total 104 results

Medi Pharma Vision
Brno University Hospital; Veterinary Research Institute

Completed

Monitoring the Efficacy of a Probiotic Dietary Supplement SmartProbio C in Patients With Severe COVID-19 Infection

COVID-19

Czechia
Medic Vision Imaging Solutions Ltd

Recruiting

Development of Protocols and Methods for Image Processing and Enhancement of Magnetic Resonance Imaging (MRI) Data.

MRI Image Enhancement

United States
MEI Pharma, Inc.

Recruiting

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Acute Myeloid Leukemia (AML) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL)

United States
MEI Pharma, Inc.

Active, not recruiting

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Colorectal Cancer

United States
I-MED Pharma

Unknown

Validation of Osmolarity System: Clinical Usability Study

Dry Eye
MEI Pharma, Inc.

Completed

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer (OVATURE)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Spain, Belgium, United Kingdom, Australia, Italy, Poland
MEI Pharma, Inc.

Completed

Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Australia
MEI Pharma, Inc.

Terminated

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)

United States, Spain, Korea, Republic of, Belgium, Taiwan, Germany, France, Italy, Australia, Poland, New Zealand, United Kingdom, Austria, Switzerland
MEI Pharma, Inc.

Terminated

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone B Cell Lymphoma | High Grade Non-Hodgkin's Lymphoma

United States, Switzerland
MEI Pharma, Inc.

Completed

A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer

Prostate Cancer

United States
Hillel Yaffe Medical Center
Medic Vision Imaging Solutions

Recruiting

Development of Protocols and Methods for Image Processing and Enhancement of MRI Data

MRI Image Enhancement

Israel
MEI Pharma, Inc.
Quotient Clinical

Completed

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143

Malignancies

United Kingdom
Mylan Inc.
Meda Pharma S.p.A.

Recruiting

Study to Evaluate the Effectiveness of Legalon®

Non-alcoholic Fatty Liver Disease (NAFLD)

Thailand
MEDA Pharma GmbH & Co. KG

Completed

Dymista Allergen Chamber - Onset of Action Study

Seasonal Allergic Rhinitis

Canada
MEDA Pharma GmbH & Co. KG

Completed

Aldara for the Treatment of Large and/or Multiple sBCC

Carcinoma, Basal Cell

France
MEDA Pharma GmbH & Co. KG

Completed

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States, Germany
MEDA Pharma GmbH & Co. KG

Completed

Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

Genital Warts

Italy
MEDA Pharma GmbH & Co. KG

Completed

Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions

Actinic Keratosis

France
MEI Pharma, Inc.
Kyowa Kirin, Inc.

Terminated

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)

United States, France, Spain, Korea, Republic of, United Kingdom, Belgium, Japan, Taiwan, Australia, Poland, Italy, Canada, Georgia, Greece, Hungary, Netherlands, New Zealand, Serbia, Turkey
MEI Pharma, Inc.
Kyowa Kirin, Inc.

Withdrawn

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL (CORAL)

CLL

United States
MEDA Pharma GmbH & Co. KG

Completed

MP-AzeFlu Allergen Chamber - Onset of Action Study

Seasonal Allergic Rhinitis

Canada
MEDA Pharma GmbH & Co. KG

Completed

DYmista NAsal Spray in CHInese Patients (DYNAS-CHI)

Allergic Rhinitis

China
MEDA Pharma GmbH & Co. KG

Completed

Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA)

Actinic Keratosis

Austria, Germany, France
MEDA Pharma GmbH & Co. KG

Completed

To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation

Atrial Fibrillation

France
MEDA Pharma GmbH & Co. KG

Recruiting

Real-world Evidence Study on Cystistat (IC/BPS)

Interstitial Cystitis and Bladder Pain Syndrome

Austria
MEDA Pharma GmbH & Co. KG

Completed

Azelastine Allergen Chamber - Onset of Action Study

Seasonal Allergic Rhinitis

Canada
MEDA Pharma GmbH & Co. KG

Completed

A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma

Basal Cell Carcinoma

Germany
MEDA Pharma GmbH & Co. KG

Completed

A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

Actinic Keratoses
MEDA Pharma GmbH & Co. KG

Completed

A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients

Actinic Keratosis
MEDA Pharma GmbH & Co. KG

Completed

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)

Diabetic Polyneuropathy

Israel, Russian Federation
I-MED Pharma
University of Waterloo

Completed

I-DROP MGD Symptomatic Relief and Tear Film Stability

Dry Eye

Canada
EIP Pharma Inc
Voisin Consulting, Inc.

Terminated

Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease

Huntington Disease

United Kingdom
MEI Pharma, Inc.
SCRI Development Innovations, LLC

Terminated

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

Solid Tumors

United States, United Kingdom
MEI Pharma, Inc.
SCRI Development Innovations, LLC

Completed

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

Solid Tumors

United States
MEDA Pharma GmbH & Co. KG
ClinResearch, GmbH; Prolytic GmbH; pharm-analyt GmbH

Completed

Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays

Allergic Rhinitis

Germany
MEDA PHARMA SPA, a Viatris company

Not yet recruiting

Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis. (Elidel-SEA)

Mild to Moderate Atopic Dermatitis
Nantes University Hospital
MEDA Pharma GmbH & Co. KG

Completed

Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face (ImiReduc)

Lentigo Maligna Melanoma (Head or Neck)

France
MEI Pharma, Inc.
SCRI Development Innovations, LLC

Completed

Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors (ME-344-001)

Solid Tumors

United States
MEDA Pharma GmbH & Co. KG
3M

Terminated

Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.

Atrial Fibrillation

Belgium, Bulgaria, France, Germany, Netherlands, Romania, Spain
Med Pharma Co., Ltd.
Fidia Farmaceutici s.p.a.

Completed

Efficacy and Safety of Intraarticular Injections of Hyalgan in the Treatment of Osteoarthritis of the Knee

Osteoarthritis

Taiwan
Ascendis Pharma Oncology Division A/S

Recruiting

TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201)

Head and Neck Neoplasms

United States, Spain, Georgia, Hungary, Germany, Italy, Taiwan
Ascendis Pharma Endocrinology Division A/S

Recruiting

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA (SkybriGHt)

Growth Hormone Deficiency

United States
Ascendis Pharma Endocrinology Division A/S

Recruiting

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin (SkyPASS)

Growth Hormone Deficiency

United States
Ascendis Pharma Endocrinology Division A/S

Active, not recruiting

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

Turner Syndrome

United States
Ascendis Pharma Endocrinology Division A/S

Active, not recruiting

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Endocrine System Diseases | Adult Growth Hormone Deficiency | Hormone Deficiency

United States, Armenia, Georgia, Greece, Ukraine, Australia, Canada, France, Israel, Italy, Japan, Malaysia, Poland, Romania, Serbia, Slovakia, Spain, Turkey, United Kingdom, Germany, Korea, Republic of
Ascendis Pharma Endocrinology Division A/S

Completed

A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

Endocrine System Diseases | Pituitary Diseases | Hormone Deficiency | Growth Hormone Deficiency, Pediatric

United States, Canada, Australia, New Zealand
Ascendis Pharma Oncology Division A/S

Recruiting

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe)

Advanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...

United States, Australia, Korea, Republic of
Ascendis Pharma Endocrinology Division A/S

Completed

A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

Endocrine System Diseases | Pituitary Diseases | Hormones | Growth Hormone Deficiency, Pediatric | hGH (Human Growth Hormone)

United States, Armenia, Australia, Belarus, Bulgaria, Georgia, Greece, Italy, New Zealand, Poland, Romania, Russian Federation, Turkey, Ukraine
Ascendis Pharma Oncology Division A/S

Recruiting

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor | Locally Advanced Solid Tumor | Neoadjuvant Melanoma | Head and Neck Squamous Cell Carcinoma HNSCC | HPV-associated Cancers | Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)

United States, Australia, Spain, Netherlands, Korea, Republic of, Taiwan
Ascendis Pharma Endocrinology Division A/S

Completed

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency (foresiGHt)

Endocrine System Diseases | Growth Hormone Deficiency | Hormone Deficiency

United States, Armenia, Georgia, Turkey, Ukraine, Australia, Canada, Denmark, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, New Zealand, Poland, Romania, Serbia, Slovakia, Spain, United Kingdom

Clinical Trials Sponsored by Medi Pharma Vision

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations